SCHEMBL6324032

SCHEMBL6324032

Cc1c(C(=O)N2CCN(C)CC2)c[nH]c1C=C1C(=O)Nc2cccc(-c3ccc(F)cc3)c21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.51
FLT3 P36888 6/20 0.46
PDGFRB P09619 6/20 0.41
KDR P35968 6/20 0.41
FLT1 P17948 3/20 0.41
CSF1R P07333 2/20 0.41
PDGFRA P16234 1/20 0.41
FGFR1 P11362 4/20 0.39
CHEK1 O14757 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
RET P07949 1/20 0.39
KIT P10721 1/20 0.39
PHKG2 P15735 1/20 0.39
FGFR3 P22607 1/20 0.39
AXL P30530 1/20 0.39
ABL2 P42684 1/20 0.39
PTK2 Q05397 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324029 1.00 EGFR (0.51) EGFRFLT3PDGFRBKDRFLT1
SCHEMBL6320593 0.92 EGFR (0.49) EGFRFLT3PDGFRBKDRFGFR1
SCHEMBL6320588 0.92 EGFR (0.49) EGFRFLT3PDGFRBKDRFGFR1
SCHEMBL6322658 0.92 EGFR (0.47) EGFRFLT3PDGFRBKDRFGFR1
SCHEMBL6321270 0.92 EGFR (0.52) EGFRFLT3PDGFRBKDRFGFR1
SCHEMBL6321268 0.92 EGFR (0.52) EGFRFLT3PDGFRBKDRFGFR1
SCHEMBL6322662 0.92 EGFR (0.47) EGFRFLT3PDGFRBKDRFGFR1
SCHEMBL6323469 0.90 EGFR (0.46) EGFRFLT3PDGFRBKDRPDGFRA
SCHEMBL6321390 0.90 EGFR (0.46) EGFRFLT3PDGFRBKDRPDGFRA
SCHEMBL6320726 0.90 EGFR (0.54) EGFRFLT3PDGFRBKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 EGFR 367/4885FLT3 596/4885PDGFRB 575/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 EGFR 367/4885FLT3 596/4885PDGFRB 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.